Home >> Business >> CAR-T Cell Therapy Market Expected to Grow at a significant CAGR of 35% from 2019-2029

CAR-T Cell Therapy Market Expected to Grow at a significant CAGR of 35% from 2019-2029

The latest market report published by Acute Market Reports “CAR-T cell Therapy Market – Growth, Future Prospects, Competitive Analysis, 2019 – 2029” the global CAR-T cell therapy market is expected to grow at a significant CAGR of 35% during the forecast period of 2021 to 2029. 

The Chimeric antigen receptor- T Cell Therapy Market is anticipated to grow at a significantly healthy CAGR of 35% during the forecast period of 2021 to 2029. The increase is primarily due to an increase in cancer patients’ rate combined with increased awareness of the therapy. This report covers all the qualitative and quantitative aspects of the Car-T Cell Therapy Market and also covers key drivers, restraints, challenges, and opportunities that are impacting the growth opportunities of the market, and its future market trends. 

Browse Full Report at https://www.acutemarketreports.com/report/car-t-cell-therapy-market-report

CAR T-cell therapy is often referred to as a type of cell-based gene therapy because it involves changing the genes within T cells to help them attack cancer. The success rate of CAR-T cell therapy varies depending on the type of cancer being treated by a healthcare professional. The market has been segmented on the basis of Type of Targeted Antigens, Type of Approach, Therapeutic Areas, Products, End Users, and by Regions. On the basis of the Approach, Autologous was valued at over US $700 Million for the year 2019 and was anticipated to grow at a compound annual growth rate of 25%  while CD19 dominated the market among targeted antigens with a lion’s share of over 70% and is expected to grow at a compound annual growth rate of 26%. On the basis of Therapeutic Areas, diffuse large B-cell lymphoma presides the market with over 56% share for the year 2019. 

According to a 2018 fact sheet published by the World Health Organization (WHO), tobacco consumption caused 7 million deaths each year. Lung cancer is the leading cause of death worldwide, accounting for 37% of all deaths. As a result, the growing number of cancer patients is expected to increase demand for CAR T-cell therapy and fuel the market’s growth during the forecast period.

North America dominated the global CAR-T Cell Therapy market in 2020, accounting for over 60 percent of the total market share. The region’s dominance is attributed to favorable reimbursement policies, rising incidences of severe lymphoblastic leukemia, early availability of CAR-T cell therapy products, and high per capita healthcare expenditure. Western Europe and Asia Pacific, followed by North America led the market. Asia Pacific and Western Europe are anticipated to be the fastest-growing regions in the CAR-T therapy market in the coming years, with and expected CAGRs of 85% and 33%, respectively during the forecast period. 

Major players of CAR-T Cell Therapy Market are Gilead Sciences, Novartis AG, Pfizer, Bluebird Bio, Sorrento Therapeutics, Celgene Corporation (Juno Therapeutics), Mustang Bio, Celyad, Fate Therapeutics, and Allogeneic Therapeutics. Market leaders are focusing on Research and Development activities and new product launches as key strategy to enhance their market share. 

Market Movements 

  • Increase in the number of cancer patients is expected to boost the need for CAR T-cell therapy across the globe.  
  • High-end commercial model, unwanted immune responses and side effects, demand and supply ratio of CAR-T Cell Therapy, are the key challenges of the market.
  • Supply has been inelastic in comparison to demand as the number of cancer patients has increased.
  • Lung cancer accounted for 37% of all deaths.
  • CD19 dominated the market with a market share of more than 70%.
  • Diffuse large B-cell lymphoma presided over the market.
  • North America dominated the global CAR-T Cell Therapy Market in 2020

The CAR T Cell Therapy Market Segmentation:

Research Period 2019-2029
Base Year 2020
Forecast Period2021-2029
Historical Year2019
UnitUSD Million
SegmentationType of Targeted Antigens (2019-2029; US$ Mn)
 By Type of Approach  (2019-2029; US$ Mn)
   By Therapeutic Areas (2019-2029; US$ Mn)
  By Product (2019-2029; US$ Mn)
  By End Users (2019-2029; US$ Mn)
 Regional  Segment (2019-2029; US$ Mn)
 Global Impact of Covid-19 Segment (2020-2021; US$   Mn)

*Detailed Segments are available on the report page

About Us

Acute Market Reports is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives.


Acute Market Reports
Address: 90 Church St, FL 1 #3514,
New York, NY 10008 United States
Toll Free(US/CANADA): +1-855-455-8662


Leave a Reply

Your email address will not be published. Required fields are marked *